cisplatin, or carboplatin and pemetrexed for up to 2 years. The overall survival in patients taking Opdivo and Yervoy was 16.8 to 21.5 (median 18.1) months, compared to 12.5 to 16.2 (median 14.1) months for patients taking chemotherapy. ...
All the patients for whom I was using [single-agent] nivolumab or pembrolizumab [Keytruda] are getting [nivolumab/relatlimab]. I still haven’t necessarily switched to use this drug in patients who I thought would get nivolumab/ipilimumab. And the longer we’re using it, the more patien...